Application Notes & Case Studies

  1. Controlling mAb Aggregates In Chromatography Process Development 5/22/2026

    Antibody aggregation remains a critical downstream challenge, particularly for complex modalities. Explore why aggregates form, why they matter, and how chromatographic strategies can help reduce risk.

  2. Multi-Technique, Vendor Neutral Analytical Data Handling For Chemists 5/21/2026

    Managing analytical data across instruments doesn’t have to slow decision-making. Learn how a vendor-neutral, multi-technique approach helps chemists access, process, and report results efficiently.

  3. Simplify And Streamline Method Development With In Silico Modeling 5/19/2026

    Automated screening paired with in silico modeling can cut method development time while improving robustness. See how combining experimentation and simulation enables faster decision‑making.

  4. LYO Cycle Development Ensures Success For Oncology Drug Scale-Up 5/14/2026

    An optimized lyophilization cycle removes excess moisture during scale‑up by adjusting drying for larger equipment, improving stability, maintaining efficiency, and supporting clinical validation.

  5. Integrated Drug Discovery: Hit To PCC In 16 Months 5/8/2026

    Accelerate your drug discovery program with integrated, cross-functional expertise that advances promising candidates from hit identification to preclinical development with speed and efficiency.

  6. How A Global Biosimilars Company Cut Manual Data Errors By 50% 5/8/2026

    Learn how a global biopharmaceutical leader halved transcription errors and integrated over 350 instruments to accelerate the development of high-quality, clinically proven biosimilars.

  7. From 51% Yield To 87% With Targeted Impurity Removal 5/7/2026

    Targeted impurity identification and purification redesign dramatically improved yield, reduced process complexity, and enabled reliable API supply for Phase II clinical development.

  8. Overcoming Product Instability And Improving Yield 5/7/2026

    Early identification of hidden product instability enabled rapid process adjustments, improving yield and keeping a preclinical toxicology program on track despite challenging reaction conditions.

  9. Producing Quality APIs At Scale 5/7/2026

    Targeted process optimization transformed an early‑phase API with yield and impurity challenges into a scalable, high‑quality manufacturing process ready to support ongoing drug development.

  10. Native SEC-MALS Characterization Using A Chromatography Data System 5/7/2026

    Native SEC‑MALS offers a calibration‑free way to accurately characterize peptide oligomers, helping scientists distinguish true higher‑order structures while avoiding bias.